tetano
Editor, Senior Moderator
J Infect Dis
. 2022 May 6;jiac167.
doi: 10.1093/infdis/jiac167. Online ahead of print.
Antibody duration after infection from SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey
Michael D Swartz[SUP] 1 [/SUP], Stacia M DeSantis[SUP] 1 [/SUP], Ashraf Yaseen[SUP] 1 [/SUP], Frances A Brito[SUP] 1 [/SUP], Melissa A Valerio-Shewmaker[SUP] 2 [/SUP], Sarah E Messiah[SUP] 3 [/SUP], Luis G Leon-Novelo[SUP] 1 [/SUP], Harold W Kohl[SUP] 4 5 [/SUP], Cesar L Pinzon-Gomez[SUP] 1 [/SUP], Tianyao Hao[SUP] 1 [/SUP], Shiming Zhang[SUP] 1 [/SUP], Yashar Talebi[SUP] 1 [/SUP], Joy Yoo[SUP] 1 [/SUP], Jessica R Ross[SUP] 1 [/SUP], Michael O Gonzalez[SUP] 1 [/SUP], Leqing Wu[SUP] 1 [/SUP], Steven H Kelder[SUP] 4 [/SUP], Mark Silberman[SUP] 6 [/SUP], Samantha Tuzo[SUP] 6 [/SUP], Stephen J Pont[SUP] 7 [/SUP], Jennifer A Shuford[SUP] 7 [/SUP], David Lakey[SUP] 8 [/SUP], Eric Boerwinkle[SUP] 1 [/SUP]
Affiliations
Abstract
Understanding the duration of antibodies to the SARS-CoV-2 virus that causes COVID-19 is important to controlling the current pandemic. Participants from the Texas Coronavirus Antibody REsponse Survey (Texas CARES) with at least one nucleocapsid protein antibody test were selected for a longitudinal analysis of antibody duration. A linear mixed model was fit to data from participants (n= 4,553) with one to three antibody tests over 11 months (10/1/2020-9/16/2021), and models fit showed that expected antibody response after COVID-19 infection robustly increases for 100 days post-infection, and predicts individuals may remain antibody positive from natural infection beyond 500 days, depending on age, body mass index, smoking or vaping use, and disease severity (hospitalized or not; symptomatic or not).
Keywords: Antibodies; Antibody Duration; COVID-19; SARS-CoV-2.
. 2022 May 6;jiac167.
doi: 10.1093/infdis/jiac167. Online ahead of print.
Antibody duration after infection from SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey
Michael D Swartz[SUP] 1 [/SUP], Stacia M DeSantis[SUP] 1 [/SUP], Ashraf Yaseen[SUP] 1 [/SUP], Frances A Brito[SUP] 1 [/SUP], Melissa A Valerio-Shewmaker[SUP] 2 [/SUP], Sarah E Messiah[SUP] 3 [/SUP], Luis G Leon-Novelo[SUP] 1 [/SUP], Harold W Kohl[SUP] 4 5 [/SUP], Cesar L Pinzon-Gomez[SUP] 1 [/SUP], Tianyao Hao[SUP] 1 [/SUP], Shiming Zhang[SUP] 1 [/SUP], Yashar Talebi[SUP] 1 [/SUP], Joy Yoo[SUP] 1 [/SUP], Jessica R Ross[SUP] 1 [/SUP], Michael O Gonzalez[SUP] 1 [/SUP], Leqing Wu[SUP] 1 [/SUP], Steven H Kelder[SUP] 4 [/SUP], Mark Silberman[SUP] 6 [/SUP], Samantha Tuzo[SUP] 6 [/SUP], Stephen J Pont[SUP] 7 [/SUP], Jennifer A Shuford[SUP] 7 [/SUP], David Lakey[SUP] 8 [/SUP], Eric Boerwinkle[SUP] 1 [/SUP]
Affiliations
- PMID: 35514141
- DOI: 10.1093/infdis/jiac167
Abstract
Understanding the duration of antibodies to the SARS-CoV-2 virus that causes COVID-19 is important to controlling the current pandemic. Participants from the Texas Coronavirus Antibody REsponse Survey (Texas CARES) with at least one nucleocapsid protein antibody test were selected for a longitudinal analysis of antibody duration. A linear mixed model was fit to data from participants (n= 4,553) with one to three antibody tests over 11 months (10/1/2020-9/16/2021), and models fit showed that expected antibody response after COVID-19 infection robustly increases for 100 days post-infection, and predicts individuals may remain antibody positive from natural infection beyond 500 days, depending on age, body mass index, smoking or vaping use, and disease severity (hospitalized or not; symptomatic or not).
Keywords: Antibodies; Antibody Duration; COVID-19; SARS-CoV-2.